Economists said Donald Trump’s plan to return trade barriers to levels not seen in generations would be “a grenade thrown in the heart” of the international system.
Citigroup sells HDFC Bank’s shares worth Rs 275 crore via block deal (28-10-2024)
American multinational Citigroup on Monday offloaded private sector lender HDFC Bank’s shares worth Rs 275 crore through an open market transaction.
Citigroup, through its arm Citigroup Global Markets Mauritius, sold 15,79,953 shares of HDFC Bank, as per the block deal data available on the BSE.
The shares were disposed of at an average price of Rs 1,742.6 apiece, taking the transaction value to Rs 275.32 crore.
Ghisallo Master Fund LP acquired the shares of Mumbai-headquartered HDFC Bank at the same price.
Shares of HDFC Bank fell 0.48 per cent to close at Rs 1,734.30 per piece on the BSE.
On October 19, HDFC Bank reported a 6 per cent increase in the September quarter net profit to Rs 17,825.91 crore on a consolidated basis.
On a standalone basis, the largest private sector lender’s post-tax net profit grew to Rs 16,820.97 crore during the reporting period against Rs 15,976.11 crore in the year-ago period.
The company’s core net interest income grew 10 per cent to Rs 30,010 cr
CAMS Q2 Results: Profit jumps 45% to Rs 122 crore (28-10-2024)
“Our overall assets under service touched a lifetime high of Rs 45 lakh crore, with the quarter recording the highest ever asset accretion. Strong retail participation in equity assets via SIPs and NFOs catapulted our equity net-sales to touch nearly Rs 1 lakh crore during the second quarter and record a staggering 59 per cent y-o-y growth in equity asset base,” the company’s CEO Anuj Kumar said.
EFC – Entrepreneurial Facilitation Centre (28-10-2024)
Btw, Mukesh on twitter is the best handle when it comes to forensics.
Federal Bank Q2 Results: Profit rises 11% to Rs 1,057 crore, NII up 15% (28-10-2024)
The total income increased to Rs 7,541 crore during the quarter under review against Rs 6,186 crore in the same quarter last year, Federal Bank said in a regulatory filing.
Index funds see growing retail participation, boost SIP flow contributions (28-10-2024)
Inflows via SIP cross Rs 1,000 cr; Share in total SIP inflows nears 5%
EFC – Entrepreneurial Facilitation Centre (28-10-2024)
just saw a post on Twitter, there is apparently a gap between Consolidated and sum of the standalone on Twitter
is this true and possible, and if yes, then what can explain ?
EFC – Entrepreneurial Facilitation Centre (28-10-2024)
More interesting stuff
Markets snap five-day losing streak as geopolitical tensions ease (28-10-2024)
ICICI Bank propels Sensex to best session in a month
Supriya Lifescience Ltd – pure play API (28-10-2024)
Q2 FY2025 Conference call Highlights:
Opening Remarks:
Revenue increase 19% YoY.
EBIDTA increase 104% YoY.
PAT increase 93% YoY.
CDO/CDMO Ambernath facility started from Q4 FY2024 for finished formulations. 70KL.
Manufacturing block (E block) at Lote Parshuram, which will increase total capacity from 597 KL (76% utilization, optimum) to 1,020 KL by Q3 FY25. It will take 1.5 to 2 years to take reach max. capacity.
Guidance:
Confident of 20% Revenue growth with high margin.
Revenue target of 1000cr. by FY2027 with high margin. Very conservative guidance.
CDO/CDMO to diversify revenue stream.
Margin guidance is 30 to 34% on yearly base due to new products.
Margin :
Backward integration helps in increase in margin. Many products manufactured up to 8 steps backward integrated.
Regulated markets have higher margin.
New products will be added in next quarter, which will have slight dip in margin due to first roll out in semi regulated margin and then to regulated market.
Cancer oral detection kit: filing patent for many countries, expected to start clinical trails. Revenue may come after 3 years.
CDO/CDMO opportunity:
Full effect will be in 2 years. In next 3 years, should contribute to 20% of revenue.
No capex, next wave will be in Patalgana after 2 to 3 years.
Once DSM project complete, bigger opportunity may come.
Margins will be similar. Formulation will have higher margin.
China:
Supriya do not produce any product which is produced in INDIA. They compete with China, as Chinese plants do not have GMP or any certification. Do not negotiate for price as Supriya is GMP, USFDA certified plant.
Others:
52% revenue from regulated market, remaining from semi regulated market and domestic market.
Diversify product portfolio and not dependent on any key raw material. Raw material Available cheaply and widely available.
H2 will be better then H1 on overall basis.
Latin American market is improving and will continue progress as registration continue.
H2 will be better then H1 on overall basis.
Latin American market is improving and will continue progress as registration continue.
D: Invested